Ginkgo Bioworks Q2 revenue falls 11%

Overview

• Ginkgo Q2 2025 rev falls to $50 mln, down from $56 mln yr/yr

• Cell Engineering rev rises 8% to $39 mln, driven by biopharma growth

• Biosecurity rev declines to $10 mln from $20 mln yr/yr

• Co achieves $250 mln cost-reduction target ahead of schedule

Outlook

• Ginkgo reaffirms 2025 total revenue of $167-$187 mln

• Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln

• Ginkgo expects 2025 Biosecurity revenue of at least $40 mln

• Ginkgo aims for Adjusted EBITDA breakeven by end of 2026

Result Drivers

• CELL ENGINEERING GROWTH - Cell Engineering revenue rose 8% to $39 mln, driven by demand from biopharma and government customers

• BIOSECURITY DECLINE - Biosecurity revenue fell to $10 mln, impacted by reduced demand compared to prior year

• COST REDUCTION - Achieved $250 mln annualized cost-reduction target ahead of schedule, aiding improved adjusted EBITDA

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 74.5% below its August 6 closing price of $13.96

Press Release: ID:nPn5rPwLwa